FDA Advisory Panel Mulls Genomic-Driven Strategies for Predictive Safety, Sample Collection

At a recent advisory committee meeting, the FDA discussed plans to develop a pre-market adverse events capture system that would employ strategies such as pharmacogenomics, system biology approaches, and biostatistics. In addition, the agency sought the committee's advice on how to encourage drug sponsors to collect genomic data more routinely as part of early clinical trials.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.